- Home
- ANGH vs ANTX Comparison
ANGH vs ANTX Comparison
Compare ANGH & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- ANTX
- Stock Information
- Founded
- ANGH 2012
- ANTX 2017
- Country
- ANGH United Arab Emirates
- ANTX United States
- Employees
- ANGH N/A
- ANTX N/A
- Industry
- ANGH Telecommunications Equipment
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- ANTX Health Care
- Exchange
- ANGH Nasdaq
- ANTX Nasdaq
- Market Cap
- ANGH 32.1M
- ANTX 33.2M
- IPO Year
- ANGH N/A
- ANTX 2022
- Fundamental
- Price
- ANGH $0.56
- ANTX $1.10
- Analyst Decision
- ANGH
- ANTX Buy
- Analyst Count
- ANGH 0
- ANTX 2
- Target Price
- ANGH N/A
- ANTX $2.00
- AVG Volume (30 Days)
- ANGH 35.5K
- ANTX 95.4K
- Earning Date
- ANGH 07-22-2025
- ANTX 08-12-2025
- Dividend Yield
- ANGH N/A
- ANTX N/A
- EPS Growth
- ANGH N/A
- ANTX N/A
- EPS
- ANGH N/A
- ANTX N/A
- Revenue
- ANGH $78,093,405.00
- ANTX N/A
- Revenue This Year
- ANGH N/A
- ANTX N/A
- Revenue Next Year
- ANGH N/A
- ANTX N/A
- P/E Ratio
- ANGH N/A
- ANTX N/A
- Revenue Growth
- ANGH 88.72
- ANTX N/A
- 52 Week Low
- ANGH $0.42
- ANTX $0.87
- 52 Week High
- ANGH $1.08
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- ANGH 58.70
- ANTX 48.42
- Support Level
- ANGH $0.47
- ANTX $1.05
- Resistance Level
- ANGH $0.65
- ANTX $1.10
- Average True Range (ATR)
- ANGH 0.04
- ANTX 0.04
- MACD
- ANGH 0.01
- ANTX 0.00
- Stochastic Oscillator
- ANGH 48.33
- ANTX 50.00
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.